Funding for this research was provided by:
Received: 14 March 2022
Accepted: 8 June 2022
First Online: 21 June 2022
: The study protocol was reviewed by the Advarra Institutional Review Board (IRB) and received an exemption determination on April 2, 2021.
: Not applicable.
: At the time this research was conducted Jennifer Duryea was an employee of Outcomes Insights, Inc. Kathleen Fox was a contract worker for Amgen but received no stock or stock options. Robert Rubin was a consultant to Amgen. Pooja Desai was an Amgen employee with Amgen stock. Mark Danese was an employee and owner of Outcomes Insights, Inc., the organization funded to conduct this research.